Invesco Ltd. Has $205.73 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Invesco Ltd. boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 40.2% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,572,189 shares of the biotechnology company's stock after acquiring an additional 1,596,948 shares during the period. Invesco Ltd. owned 2.02% of Exelixis worth $205,725,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Exelixis by 32.2% in the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock valued at $201,000 after buying an additional 1,328 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Exelixis in the 4th quarter valued at $17,046,000. Park Avenue Securities LLC grew its holdings in shares of Exelixis by 10.6% in the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after buying an additional 707 shares during the period. Envestnet Asset Management Inc. grew its holdings in shares of Exelixis by 23.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock valued at $9,159,000 after buying an additional 47,845 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new position in shares of Exelixis in the 1st quarter valued at $233,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Stephens raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $29.00 to $60.00 in a report on Tuesday, June 24th. Benchmark reissued a "neutral" rating on shares of Exelixis in a report on Monday, June 23rd. Barclays boosted their price target on shares of Exelixis from $29.00 to $40.00 and gave the company an "equal weight" rating in a report on Thursday, July 10th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a "buy" rating in a report on Tuesday, June 24th. Finally, UBS Group set a $38.00 target price on shares of Exelixis and gave the stock a "neutral" rating in a research note on Wednesday, July 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and an average target price of $44.06.

Exelixis Price Performance

NASDAQ:EXEL traded down $0.16 on Friday, hitting $38.31. 2,370,582 shares of the company's stock were exchanged, compared to its average volume of 3,938,011. The firm has a 50-day moving average price of $41.96 and a 200-day moving average price of $39.15. Exelixis, Inc. has a 52 week low of $25.12 and a 52 week high of $49.62. The company has a market cap of $10.31 billion, a P/E ratio of 18.42, a price-to-earnings-growth ratio of 0.80 and a beta of 0.29.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. During the same period in the previous year, the firm posted $0.84 EPS. The company's revenue for the quarter was down 10.8% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, Director Tomas J. Heyman sold 4,544 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $44.29, for a total value of $201,253.76. Following the sale, the director directly owned 32,470 shares of the company's stock, valued at approximately $1,438,096.30. This represents a 12.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sue Gail Eckhardt sold 18,838 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $42.74, for a total transaction of $805,136.12. Following the completion of the sale, the director owned 21,380 shares of the company's stock, valued at $913,781.20. This trade represents a 46.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,304 shares of company stock valued at $2,846,164. Corporate insiders own 2.82% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.